Anouk Donners

64 Chapter 3 20. de Maistre E, Wahl D, Perret-Guillaume C, Regnault V, Clarac S, Briquel ME, Andre E, Lecompte T. A chromogenic assay allows reliable measurement of factor VIII levels in the presence of strong lupus anticoagulants. Thromb Haemost. 1998; 79: 237-238. 21. Tang N, Yin S. An Easy Method to Eliminate the Effect of Lupus Anticoagulants in the Coagulation Factor Assay. Clin Lab. 2016; 62: 1363-1365. 22. Rodgers S, Duncan E. Chromogenic Factor VIII Assays for Improved Diagnosis of Hemophilia A. Methods Mol Biol. 2017; 1646: 265-276. 23. Feng L, Zhao Y, Zhao H, Shao Z. Effects of storage time and temperature on coagulation tests and factors in fresh plasma. Sci Rep. 2014; 4: 3868. 24. Toulon P, Metge S, Hangard M, Zwahlen S, Piaulenne S, Besson V. Impact of different storage times at room temperature of unspun citrated blood samples on routine coagulation tests results. Results of a bicenter study and review of the literature. Int J Lab Hematol. 2017; 39: 458-468. 25. Bohm M, Taschner S, Kretzschmar E, Gerlach R, Favaloro EJ, Scharrer I. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease. Blood Coagul Fibrinolysis. 2006; 17: 39-45. 26. Favaloro EJ, Soltani S, McDonald J. Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing. Am J Clin Pathol. 2004; 122: 686-692. 27. Zurcher M, Sulzer I, Barizzi G, Lammle B, Alberio L. Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature. Thromb Haemost. 2008; 99: 416-426. 28. European Medicines Agency. Guideline on bioanalytical method validation, 2011. https://www.ema. Accessed on 16-08-2017. 29. El Amrani M, van den Broek MP, Gobel C, van Maarseveen EM. Quantification of active infliximab in human serum with liquid chromatography-tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard: A target-based, sensitive and cost-effective method. J Chromatogr A. 2016; 1454: 42-48. 30. El Amrani M, Bosman SM, Egas AC, Hack CE, Huitema ADR, van Maarseveen EM. Simultaneous quantification of free adalimumab and infliximab in human plasma using a target-based sample purification and liquid chromatography-tandem mass spectrometry. Therapeutic Drug Monitoring. 2019; 41: 640-647.